Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03837899 · ClinicalTrials.gov registry record · Phase 1

Durvalumab and Tremelimumab for Pediatric Malignancies

A Phase 1 study of Pediatric Cancer and Hematological Malignancies, sponsored by AstraZeneca.

Active
Registry status
Phase 1
Development phase
50
Enrollment target
19
Study locations

NCT03837899 is a Phase 1 study of Pediatric Cancer and Hematological Malignancies that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 50 participants, below the 1,490-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (97% lower). The trial reports 19 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03837899, a Phase 1 study of Pediatric Cancer and Hematological Malignancies, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
19
Study locations

Study Summary

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.

Conditions Studied

Pediatric Cancer Hematological Malignancies Solid Tumor Pediatric

Interventions

  • DRUG Durvalumab / Tremelimumab Combination Therapy

Study Locations (19)

Other

  • Research Site - Lille
  • Research Site - Marseille
  • Research Site - Paris
  • Research Site - Cologne
  • Research Site - Genova
  • Research Site - Milan
  • Research Site - Rome
  • Research Site - Torino
  • Research Site - Utrecht
  • Research Site - Barcelona
  • Research Site - Madrid
  • Research Site - Leeds
  • Research Site - London
  • Research Site - Sutton

Maryland

  • Research Site - Baltimore

Massachusetts

  • Research Site - Boston

New York

  • Research Site - New Hyde Park

Oklahoma

  • Research Site - Oklahoma City

South Carolina

  • Research Site - Charleston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2019-03-07
Est. Completion 2024-12-30
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03837899

The ClinicalTrials.gov registry entry for NCT03837899 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,490-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (97% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pediatric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Durvalumab / Tremelimumab Combination Therapy is the first listed.

NCT03837899 reports 19 study locations spanning 6 distinct geographic areas - top geographies include Other, Maryland, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03837899 about?

NCT03837899 is a clinical study titled "Durvalumab and Tremelimumab for Pediatric Malignancies". The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.

What is the current status of trial NCT03837899?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2019-03-07. Estimated completion is 2024-12-30.

What conditions does trial NCT03837899 study?

This clinical trial studies the following conditions: Pediatric Cancer, Hematological Malignancies, Solid Tumor Pediatric.

What interventions are being tested in trial NCT03837899?

The interventions under investigation include: Durvalumab / Tremelimumab Combination Therapy (DRUG).

Who is sponsoring clinical trial NCT03837899?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03837899 being conducted?

This trial has 19 study locations across Maryland, Massachusetts, New York, Oklahoma, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pediatric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pediatric Cancer

All registered trials for this condition

Hematological Malignancies

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.